Multiple Sclerosis
Conference Coverage
Trial of clozapine, risperidone halted in MS
SAN DIEGO – Adverse events led to participants’ withdrawal.
Literature Review
MAGNIMS and McDonald Criteria Have Similar Accuracy
The 2016 Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) criteria have accuracy similar to that of the 2010 McDonald criteria in...
Literature Review
Rituximab May Provide Greater Benefits Than Other First-Line MS Therapies
Rituximab is associated with a lower drug discontinuation rate than all other commonly prescribed disease-modifying treatments (DMTs) used as...
Commentary
MS: Past, Present, and Future
Stuart D. Cook, MD, and Abdul Rahman Alchaki, MDDr. Cook is the Ruth Dunietz Kushner and Michael Jay Serwitz Professor of Neurology/Neurosciences...
Conference Coverage
VIDEO: Managing the alemtuzumab paradox
SAN DIEGO – Dr. Alasdair Coles explains the best management approach for this “high risk, high gain” drug.
Conference Coverage
Third course of alemtuzumab can improve MS outcomes
SAN DIEGO – Patients who experience radiographic relapse after two courses of alemtuzumab may not be treatment failures.
Conference Coverage
Switching RRMS patients to daclizumab beta appears safe
SAN DIEGO – A post hoc analysis from the DECIDE study sheds light on the efficacy of transitioning patients from glatiramer acetate to daclizumab...
Conference Coverage
VIDEO: Oral ozanimod shows promise for relapsing MS
SAN DIEGO – The drug is currently being evaluated by the Food and Drug Administration for relapsing multiple sclerosis.
Conference Coverage
VIDEO: Efficacy of DMTs decreases with age
SAN DIEGO – A meta-analysis offers new insights into the age-dependent efficacy of multiple sclerosis treatments.
Conference Coverage
VIDEO: New MS ambulatory measure could fill clinical gap
SAN DIEGO – Dr. Emily Evans explains how the single-item instruments measure up to existing ambulatory scales.
Conference Coverage
VIDEO: Alemtuzumab associated with long-term MS control in TOPAZ study
SAN DIEGO – Extension study reveals durable benefit at 7 years.